Is Olaparib on Medicare?
Olaparib has been approved by the State Food and Drug Administration in 2018 to enter the domestic market and is sold under the trade name Lipuzhuo. It is a drug used to treat cancer. If Patients whose cancers have specific genetic markers (abnormal "BRCA" or "HRR" genes) may be treated with Lynparza. Its efficacy and study results vary by patient group and cancer type, and not everyone responds to Lynparza treatment.
After being launched in China, Lynparza has entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Administration, but it is only available to patients who meet the indications. Patients who do not meet the conditions can only purchase it at their own expense. Reimbursement conditions for olaparib include maintenance treatment of previously untreated adult patients with germline or somatic BRCA mutations (gBRCAm or sBRCAm) with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after achieving complete response or partial response to first-line platinum-containing chemotherapy; platinum-sensitive Maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after achieving complete or partial response to platinum-containing chemotherapy; adult patients with metastatic castration-resistant prostate cancer who harbor a germline or somatic BRCA mutation (gBRCAm or sBRCAm) and have failed prior therapy, including a novel endocrine agent.
The price of each box of 150mg*56 tablets of Lynparza sold domestically may be around RMB 6,000. There are price differences for drugs of different specifications, and reimbursement ratios are different in different regions. The price after reimbursement may be different. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)